Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity (Q61626183)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity |
article |
Statements
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity (English)
Cornelis J M Melief
Sjoerd H van der Burg
Marij J P Welters
A Rob P M Valentijn
Margriet J G Lowik
Dorien M A Berends-van der Meer
Annelies P G Vloon
Jan W Drijfhout
Amon R Wafelman
Jaap Oostendorp
Gert Jan Fleuren
Rienk Offringa
1 January 2008